|
Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations Clinical research trials and Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations. Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations clinical trial. Human subjects often receive the most effective healthcare possible for their Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations  Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations
Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations
For Condition: Cardiovascular Diseases,Heart Diseases
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To develop a comprehensive protocol for assessing cardiovascular reactivity to stressors, for use in epidemiological and clinical investigations of cardiovascular diseases in healthy populations.
Details: BACKGROUND: Cardiovascular reactivity (CVR) is the change in a cardiovascular parameter in response to a discrete environmental stimulus. A leading theory linking behavior to cardiovascular diseases such as atherosclerosis and hypertension proposed that an exaggerated physiological response to a psychological challenge increased the risk for development of disease. Such a link had not been established conclusively in 1988. To a considerable extent, this might have been due to the fact that numerous approaches were devised to elicit and measure CVR. Furthermore, no single test or combination of tests was available which would be suitable for administering to large numbers of individuals who differed in age, gender, cultural or ethnic background, and socioeconomic status, as would be required for definitive prospective studies of reactivity and cardiovascular disease. A conference sponsored by the NHLBI and the University of Pittsburgh in 1984 comprehensively reviewed the concept of reactivity, its measurement, and its hypothesized relationship to a disease process. The value of CVR is that it provides an estimation of the changes in cardiovascular function in response to the challenges of daily life, and thus may serve as a better marker or predictor of cardiovascular disease risk than the usual 'casual' measurements. Essential hypertension appears to be a multi-factorially determined disorder, whose etiology encompasses different elements for different individuals. Physiological changes induced by excessive cardiovascular reactivity are among the mechanisms suggested to account for the transition from borderline to established hypertension. In this model, episodic cardiovascular activation elicited by behavioral challenges leads to autoregulatory adjustments culminating in elevated blood pressure. An alternative interpretation is that both elevated CVR and elevated blood pressure are reflections of underlying nervous system pathology. Prospective studies, using appropriate behavioral designs and a standardized protocol to assess cardiovascular reactivity could distinguish between these alternatives. The possible role of cardiovascular reactivity in coronary heart disease was supported by evidence from both basic and clinical studies. The hemodynamic forces resulting from turbulence and shear stress at curves and bifurcations of the coronary arteries had been cited as responsible for the greater degree of atherosclerosis in high heart rate, as opposed to low heart rate animals. Monkeys with large elevations of heart rate in response to psychological arousal developed significantly more atherosclerosis. Although the above findings had not been confirmed in humans as of 1988, a substantial majority of studies reported greater reactivity of Type A subjects during stress. Although the evidence was suggestive and the mechanism plausible, stress-induced cardiovascular reactivity had not been investigated as a risk factor for cardiovascular disease. In addition to basic research to determine the parameters and physiological determinants of reactivity, clinical and epidemiological studies were needed to establish whether this association was reliable. Especially needed were prospective, longitudinal studies of the association between reactivity and disease. The Clinical Applications and Prevention Advisory Committee of the National Heart, Lung, and Blood Institute recommended the development of this study in February 1987. The National Heart, Lung, and Blood Advisory Council approved the concept in May 1987. A Request for Applications was released in August 1987 and awards made in July 1988. DESIGN NARRATIVE: Investigators at the University of Miami evaluated cardiovascular and hormonal functions at rest and after standardized manipulations designed to evoke autonomic nervous system arousal. Two hundred and fifty-six subjects were enrolled into a 2 (male, female) x 2 (Black, white) x 2 (25-44 years, 55-64 years) x 2 (Miami, Durham) design. Subjects were compared across a broad range of socioeconomic status. Each subject was scheduled for three laboratory sessions. Sessions 1 and 2 were two weeks apart. Session 3 was six months later. During the sessions, individuals were subjected to a forehead cold pressor stimulus, a video game, and an evaluative speech stressor. Noninvasive cardiovascular measures assessed included heart rate, cardiac output, peripheral resistance, Heather Index, pre-ejection period, left ventricular ejection period, and diastolic, systolic, and mean arterial blood pressure. On the same day as the laboratory session, subjects wore an ambulatory impedance and electrocardiogram monitor at work and at home. The following day subjects wore an ambulatory blood pressure monitor at work and at home. Data were analyzed in terms of stability of baseline values, differences in laboratory reactivity between groups, differences in reactivity between tasks, reliability of responses to tasks across sessions, differences in reactivity as an individual difference variable, and generalizability of reactivity in the laboratory to cardiovascular function observed in more naturalistic settings. Improved procedures were developed for monitoring impedance cardiographic and electrocardiographic activity. Investigators at the University of Pittsburgh developed a battery of tests to elicit differential vascular, cardiac inotropic and chronotropic responses. Each task was based on a computer-driven video game which permitted a standardized task presentation and multiple response measurement. During the initial prototyping year, items were selected to maximize reliability, validity, and applicability to diverse demographic groups. Circadian ambulatory studies in this year established optimal baselines for reactivity assessment.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Male
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
NeilSchneiderman, ,
Additional Information:
Study ID Numbers: 1111;
Study Start Date: July 1988
Record last reviewed: June 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005231
Other Cardiovascular Diseases Studies:
1. Coronary-Prone Behavior and Cardiovascular Reactivity
2. Coronary Disease Morbidity and Mortality in a Population
3. Promoting Long Term Dietary Change to Reduce CVD Risk
4. Exercise Adherence in a Behavioral Weight Loss Program
5. Insulin Resistance and Blood Pressure Regulation in Blacks
Related Studies:
Other Cardiovascular Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations
|
|
|
|
|
|
|
|
